PLK1 and colorectal carcinoma: Consistently, pharmacological inhibition with CDC7 inhibitors (XL413 or PHA767491) overcomes resistance to oxaliplatin in cells, assayed using proliferation, colony formation, and tumorsphere formation CRC cells (Figure 6B–E; Figure S6A–C, Supporting Information), which recapitulated the phenotypes of PLK1 inhibitor.